Spero Therapeutics, Inc. Gain (Loss) on Sale of Derivatives
Spero Therapeutics, Inc. (SPRO) reported Gain (Loss) on Sale of Derivatives of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnSaleOfDerivatives · last filed 2024-03-13
- Spero Therapeutics, Inc. gain (loss) on sale of derivatives for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Spero Therapeutics, Inc. gain (loss) on sale of derivatives for the quarter ending 2023-09-30 was $0.00.
- Spero Therapeutics, Inc. gain (loss) on sale of derivatives for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Spero Therapeutics, Inc. gain (loss) on sale of derivatives for the quarter ending 2023-03-31 was $0.00.
- Spero Therapeutics, Inc. gain (loss) on sale of derivatives for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Spero Therapeutics, Inc. gain (loss) on sale of derivatives for fiscal 2022 was $917.00K, a 349.51% increase from fiscal 2021.
- Spero Therapeutics, Inc. gain (loss) on sale of derivatives for fiscal 2021 was $204.00K.
- Spero Therapeutics, Inc. gain (loss) on sale of derivatives for fiscal 2019 was $223.00K.
| Period end | Gain (Loss) on Sale of Derivatives 3 month | Gain (Loss) on Sale of Derivatives 6 month | Gain (Loss) on Sale of Derivatives 9 month | Gain (Loss) on Sale of Derivatives 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $0.00 derived: sum of 2 quarters · filed 2024-03-13 | $0.00 derived: sum of 3 quarters · filed 2024-03-13 | $0.00 10-K · filed 2024-03-13 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | $141.00K derived: sum of 4 quarters · filed 2024-03-13 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $141.00K derived: sum of 3 quarters · filed 2024-03-13 | $115.00K derived: sum of 4 quarters · filed 2024-03-13 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | $141.00K derived: sum of 2 quarters · filed 2024-03-13 | $115.00K derived: sum of 3 quarters · filed 2024-03-13 | $1.11M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-12-31 | $141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $115.00K derived: sum of 2 quarters · filed 2024-03-13 | $1.11M derived: sum of 3 quarters · filed 2024-03-13 | $917.00K 10-K · filed 2024-03-13 |
| 2022-09-30 | -$26.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $969.00K derived: sum of 2 quarters · filed 2023-11-13 | $776.00K 10-Q · filed 2023-11-13 | $980.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $995.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $802.00K 10-Q · filed 2023-08-10 | $1.01M derived: sum of 3 quarters · filed 2023-08-10 | $1.01M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$193.00K 10-Q · filed 2023-05-11 | $11.00K derived: sum of 2 quarters · filed 2023-05-11 | $11.00K derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $204.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $204.00K derived: sum of 2 quarters · filed 2023-03-30 | $204.00K 10-K · filed 2023-03-30 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-10 | |||
| 2019-12-31 | $223.00K 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |